Carlsmed, Inc. (CARL) EBITDA
- 2026-06-30: Basis Reported; EBITDA -$10.91M*; Operating income -$11.04M; Depreciation and amortization $130.00K*.
- 2026-03-31: Basis Reported; EBITDA -$9.18M; Operating income (m); Depreciation and amortization (m).
- 2025-12-31: Basis Reported; EBITDA -$9.22M; Operating income (m); Depreciation and amortization (m).
- 2025-09-30: Basis Reported; EBITDA -$8.95M*; Operating income -$9.04M; Depreciation and amortization $82.00K*.
Complete source-backed ebitda history.
- Available history
- 2024-12-31 to 2026-03-31
- Data captured
Historical EBITDA
EBITDA 3 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|
| 2026-06-30 | Reported | -$10.91M* | -$11.04M | $130.00K* | (m) | (m) | $121.00K* | -$7.36M* | (m) | $6.04M | (m) | $0.00 |
|---|
| 2026-03-31 | Reported | -$9.18M | (m) | (m) | (m) | -56.94% | $79.00K | -$13.01M | (m) | $5.18M | (m) | $0.00 |
|---|
| 2025-12-31 | Reported | -$9.22M | (m) | (m) | (m) | -60.80% | (m) | (m) | (m) | (m) | (m) | (m) |
|---|
| 2025-09-30 | Reported | -$8.95M* | -$9.04M | $82.00K* | (m) | (m) | $159.00K* | -$8.46M* | (m) | $4.45M | (m) | $0.00 |
|---|
| 2025-06-30 | Reported | -$6.44M* | -$6.50M | $61.00K* | (m) | (m) | $327.00K* | -$7.04M* | (m) | $4.16M | (m) | $0.00 |
|---|
| 2025-03-31 | Reported | -$5.68M | (m) | (m) | (m) | -55.74% | $83.00K | -$8.15M | (m) | $3.15M | (m) | $0.00 |
|---|
| 2024-12-31 | Reported | -$4.66M | (m) | (m) | (m) | -49.53% | (m) | (m) | (m) | (m) | (m) | (m) |
|---|
| 2024-09-30 | Reported | -$7.74M* | -$7.78M | $33.00K* | (m) | (m) | $52.00K* | -$7.58M* | (m) | $4.04M | (m) | $0.00 |
|---|
| 2024-06-30 | Reported | (m) | -$6.32M | (m) | (m) | (m) | (m) | (m) | (m) | $4.00M | (m) | $0.00 |
|---|
EBITDA 12 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|
| 2025-12-31 | Reported | -$30.29M | (m) | (m) | (m) | -59.97% | $642.00K | -$28.98M | (m) | $17.02M | (m) | $0.00 |
|---|
| 2024-12-31 | Reported | -$23.98M | (m) | (m) | (m) | -88.26% | $180.00K | -$25.47M | (m) | $14.30M | (m) | $0.00 |
|---|